{"schema_version":"1.0","type":"article","title":"NVIDIA Enters Pharma: BMS Readies 576 GPUs as Lilly Commits Up to $1 Billion","url":"https://drugnews.com.tw/articles/2026-08-20-big-pharma-ai-arms-race-nvidia-bms-lilly-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-08-20-big-pharma-ai-arms-race-nvidia-bms-lilly-en.md","lang":"en","date":"2026-08-20","publish_at":"2026-08-20T08:00:00+08:00","updated_at":"2026-08-20","category":"商業分析系列","topic":"商業分析系列","tags":["AI drug discovery","NVIDIA","Bristol Myers Squibb","Eli Lilly","Roche","drug development","GPU infrastructure","Taiwan semiconductor supply chain"],"summary":"BMS is preparing to deploy what NVIDIA's published specifications imply is a 576-GPU Rubin system, while Lilly and NVIDIA plan to commit up to $1 billion over five years. The real contest is whether proprietary data, wet-lab execution and clinical evidence can become one learning loop.","key_points":[],"facts":[],"sections":["01 | BMS is building three layers at once","02 | Big Pharma is buying an entire R&D factory","03 | AI can move faster, but the drug still has to work in people","04 | Taiwan has a role, but a supply-chain list is not a purchase order","Conclusion | The final judge is still the patient's clinical outcome","References","Disclaimer"],"references":[{"title":"[Bristol Myers Squibb: building an NVIDIA Vera Rubin AI factory]","source":"","date":"","url":"https://news.bms.com/news/corporate-financial/2026/Bristol-Myers-Squibb-to-Build-the-Most-Powerful-AI-Factory-in-Life-Sciences-with-NVIDIA/default.aspx"},{"title":"[NVIDIA: BMS to deploy eight DGX Vera Rubin NVL72 systems]","source":"","date":"","url":"https://blogs.nvidia.com/blog/bristol-myers-squibb-building-life-science-industrys-most-advanced-ai-factory-on-nvidia-vera-rubin/"},{"title":"[NVIDIA: DGX Vera Rubin NVL72 specifications]","source":"","date":"","url":"https://www.nvidia.com/en-us/data-center/dgx-vera-rubin-nvl72/"},{"title":"[Bristol Myers Squibb: Claude Enterprise rollout to more than 30,000 employees]","source":"","date":"","url":"https://news.bms.com/news/corporate-financial/2026/Bristol-Myers-Squibb-Announces-Strategic-Agreement-with-Anthropic-to-Position-Claude-Enterprise-as-the-Shared-Intelligence-Platform-Across-Its-Global-Operations/default.aspx"},{"title":"[Schrödinger: Bunsen early access for molecular discovery]","source":"","date":"","url":"https://ir.schrodinger.com/press-releases/news-details/2026/Schrdinger-Introduces-Bunsen-an-AI-Co-Scientist-for-Molecular-Discovery/default.aspx"},{"title":"[Eli Lilly: five-year NVIDIA co-innovation laboratory commitment of up to $1 billion]","source":"","date":"","url":"https://investor.lilly.com/news-releases/news-release-details/nvidia-and-lilly-announce-co-innovation-ai-lab-reinvent-drug"},{"title":"[Roche: addition of 2,176 Blackwell GPUs]","source":"","date":"","url":"https://www.roche.com/media/releases/med-cor-2026-03-16"},{"title":"[Merck & Co.: multiyear Google Cloud collaboration of up to $1 billion]","source":"","date":"","url":"https://www.merck.com/news/merck-and-google-cloud-partner-to-accelerate-agentic-ai-enterprise-transformation/"},{"title":"[Novo Nordisk: strategic collaboration with OpenAI]","source":"","date":"","url":"https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916532"},{"title":"[Sanofi: equity investment in Owkin and a three-year research collaboration]","source":"","date":"","url":"https://www.sanofi.com/en/media-room/press-releases/2021/2021-11-18-06-30-00-2336966"},{"title":"[Nature Medicine: randomized Phase 2a study of rentosertib]","source":"","date":"","url":"https://www.nature.com/articles/s41591-025-03743-2"},{"title":"[ClinicalTrials.gov: rentosertib study NCT05938920]","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT05938920"},{"title":"[MindRank: first participant dosed in the Chinese Phase 3 study of MDR-001]","source":"","date":"","url":"https://www.mindrank.ai/en/news/detail/155"},{"title":"[Drug Discovery Today: 2024 review of clinical success rates for AI-discovered drugs]","source":"","date":"","url":"https://pubmed.ncbi.nlm.nih.gov/38692505/"},{"title":"[NVIDIA: Vera Rubin production and Taiwan supply-chain partners]","source":"","date":"","url":"https://nvidianews.nvidia.com/news/vera-rubin-full-production-agentic-ai-factory"},{"title":"[NVIDIA: Taiwan's AI infrastructure ecosystem]","source":"","date":"","url":"https://blogs.nvidia.com/blog/taiwan-ecosystem-ai-infrastructure/"},{"title":"Verification cutoff: August 11, 2026.","source":"","date":"","url":""}],"images":[{"alt":"Figure 1 | Big Pharma's 2026 AI commitments span compute, cloud, enterprise agents and laboratory infrastructure; announced spending limits and capacity are not clinical outcomes","url":"https://drugnews.com.tw/assets/articles/big-pharma-ai-arms-race-nvidia-bms-lilly-en/figure-01.png"},{"alt":"Figure 2 | The evidence ladder runs from compute and agents through wet-lab work and candidate nomination to clinical trials; a small early Phase 1 review cannot be extrapolated into approval probability","url":"https://drugnews.com.tw/assets/articles/big-pharma-ai-arms-race-nvidia-bms-lilly-en/figure-02.png"},{"alt":"Figure 3 | Taiwan sits across the AI infrastructure chain, but participation in NVIDIA's ecosystem is not evidence of a specific BMS or Roche order","url":"https://drugnews.com.tw/assets/articles/big-pharma-ai-arms-race-nvidia-bms-lilly-en/figure-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/big-pharma-ai-arms-race-nvidia-bms-lilly-en/cover-1400.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-08-20）。NVIDIA Enters Pharma: BMS Readies 576 GPUs as Lilly Commits Up to $1 Billion。https://drugnews.com.tw/articles/2026-08-20-big-pharma-ai-arms-race-nvidia-bms-lilly-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh":"2026-08-20-big-pharma-ai-arms-race-nvidia-bms-lilly.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}